SCHEMBL6859192

SCHEMBL6859192

CC(=O)S[C@H]1C[C@@H](COc2ccccc2)N(S(=O)(=O)c2ccc3ccccc3c2)C1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 8/20 0.43
CASP7 P55210 6/20 0.43
ECE1 P42892 4/20 0.42
MME P08473 2/20 0.42
ACE P12821 2/20 0.42
AKR1C3 P42330 3/20 0.41
AKR1C1 Q04828 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CASP1 P29466 1/20 0.40
CASP2 P42575 1/20 0.40
CASP4 P49662 1/20 0.40
CASP9 P55211 1/20 0.40
CASP6 P55212 1/20 0.40
CASP8 Q14790 1/20 0.40
CCR4 P51679 1/20 0.39
MCL1 Q07820 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7684327 1.00 CASP3 (0.43) CASP3CASP7ECE1MMEACE
SCHEMBL6859145 0.88 CCR4 (0.41) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7688651 0.88 CCR4 (0.41) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL5405158 0.83 CASP3 (0.44) CASP3CASP7ECE1MMEACE
SCHEMBL5403947 0.82 CASP3 (0.46) CASP3CASP7ECE1MMEACE
SCHEMBL7139591 0.82 CASP3 (0.46) CASP3CASP7ECE1MMEACE
SCHEMBL7144626 0.81 AKR1C3 (0.48) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL5409789 0.81 ECE1 (0.49) CASP3CASP7ECE1MMEACE
SCHEMBL7138828 0.81 ECE1 (0.49) CASP3CASP7ECE1MMEACE
SCHEMBL5407330 0.81 ECE1 (0.49) CASP3CASP7ECE1MMEACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6790860-B2 USEFUL AS INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; EFFECTIVE IN TREATING DISEASE STATES ASSOCIATED WITH VASOCONSTRICTION HOFFMANN-LA ROCHE INC. 2004-09-14 US disclosed
US-20030199569-A1 Pyrrolidine derivatives AEBI JOHANNES (CH) 2003-10-23 US disclosed
US-20020040146-A1 Pyrrolidine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2002-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199569-A1 Pyrrolidine derivatives PREP, PEPD, MMP3 CASP3 818/4885CASP7 1467/4885ECE1 4/4885
US-20020040146-A1 Pyrrolidine derivatives PREP, PEPD, MMP3 CASP3 818/4885CASP7 1467/4885ECE1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.